COMP <GO>
PTGX vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Protagonist Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PTGX 2
— JNJ 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: PTGX
LAST: $144.85 (+0.35%) • MKT CAP: $9.34B
balance-sheet
26.00
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTGX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTGX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.70% | 25.50% | -42.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.60% | 2.97% | -2.37 | JNJ | /fcf-yield <GO> |
| Operating Margin | -6.00% | 34.70% | -40.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -5.00% | 28.50% | -33.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 0.00% | 6.00% | -6.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 5.59 | +20.41 | PTGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | PTGX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.9 | 60.4 | -2.44 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.08 | -0.09 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 23.0x | +8.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.34B | $662.49B | -$653.15B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTGX REV | JNJ REV | PTGX GROSS % | JNJ GROSS % | PTGX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | $56.1M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | $182.8M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$70.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTGX // BETA 0.99
JNJ // BETA 1.08